Researchers from the National University of Singapore (NUS) have solved a 60-year-old mystery in bacterial cell envelope ...

Dr. Jennifer Schneider discusses Centauri Therapeutics' novel approach to combating Gram-negative infections, its first ...

A team of US researchers on Sunday said it has identified a way that colistin (a potent, last-resort antibiotic) resistance ...

Antibiotic resistance among Gram‐negative bacteria represents one of the most pressing challenges in modern medicine. These pathogens have evolved multiple mechanisms to evade the effects of ...

Colistin, a last-resort antibiotic, is losing its power due to rising resistance—and the culprits might be hiding in your ...

Blacksmith Medicines, Inc. (Blacksmith), a leading biopharma dedicated to discovering and developing therapeutics targeting metalloenzymes, today announced that the United States Patent and Trademark ...

Colistin is a potent, last-resort antibiotic used only to treat people with dangerous, life-threatening bacterial infections ...

Basel-based BioVersys stands to receive CHF 5 million upfront under the terms of the deal, which could be worth up to CHF 479 ...

Colistin is a potent, last-resort antibiotic, used only to treat people with dangerous, life-threatening bacterial infections ...

Alembic to expand their U.S. commercial portfolio with FDA-approved PIVYA for the treatment of women with uncomplicated ...